You are here
AppBus and Atlantic Research Group usher in a new era of eClinical interoperability
PHILADELPHIA, April 11, 2019 /PRNewswire/ -- AppBus, an accelerator of business transformation announced the addition of another healthcare customer Atlantic Research Group (ARG), a rare disease Contract Research Organization (CRO). With AppBus eXperience Platform (AXP), ARG is now able to onboard applications within a secure smart workspace regardless of system, availability of APIs or user device. AXP has taken a months' long process riddled with pain points to a matter of days, while improving data quality and security to meet compliance and audit requirements.
Sponsors and CROs have consistently maintained a best of breed strategy to mitigate their risk and dependence on one vendor; a practice that is common across enterprise procurement departments in all software categories. Often the platforms used for processing adverse events are legacy without any APIs, requiring manual data entry.
"With AppBus we were able to integrate, automate, and deliver an adverse events workflow across multiple systems," stated Hunter Walker, CTO at Atlantic Research Group. "The innovative breakthrough for us was our ability to integrate applications that do not have APIs removing the need to touch the source code. The automation within these integrations dramatically improved the efficiency of how we process adverse events. Additionally, AXP delivers a unified audit trail, across all apps, for CRO management, and sponsor review."
ARG sought to rethink how they engage and interact with patients, sites and sponsors. With AppBus they can build on top of any technology investment and augment those systems to rapidly rollout a "study in a box". AXP architecture provides a secure, flexible and modular approach for the sponsor and ARG to increase the speed of study start-up, by providing cleaner data and a reduction of protocol deviations ensuring a successful study completion.
"Interoperability of systems is a major issue in the healthcare and life sciences markets," stated AppBus CEO, Bill Conners. "With AppBus, complex and difficult eClinical integrations are now possible at a speed not seen before. We are committed to delivering a seamless and optimized workspace to Clinical Research Professionals."
AppBus enables the consumerization of IT with intelligence, agility and ease. We empower employees to perform by delivering the right insight at the right time. AppBus automates processes and activities that matter leading to seamless and successful customer engagement. Our digital automation platform enables enterprises to increase the effectiveness of employees by providing smart workspaces on any device while simplifying processes through intelligent automation. Visit us at AppBus.com
ARG is a rare disease, oncology and immunology-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization. Founded in 2004, ARG has experienced consistent growth across the globe, expanding our reach to include drug and device trial management in diverse and wide-ranging therapeutic areas. ARG has remained true to our original vision: every project is highly significant and visible, delivered through strategic collaboration with partners. ARG successfully operationalizes development projects because we believe everyone deserves to be well.
View original content to download multimedia:http://www.prnewswire.com/news-releases/appbus-and-atlantic-research-group-usher-in-a-new-era-of-eclinical-interoperability-300830675.html
SOURCE AppBus, Inc.